cardiovascularbusiness.com -- Eptifibatide (Integrilin, Millennium Pharmaceuticals) as an adjunct to PCI in STEMI patients is equally as effective as an adjunct therapy of abciximab (ReoPro, Eli Lilly/Centocor), according to the results of the EVA-AMI trial published in the Aug. 3 edition of the Journal of the American College of Cardiology.
